A Study to Evaluate Persistence of Immune Responses After Post-exposure Prophylaxis of Rabipur® (Purified Chicken-embryo Cell Rabies Vaccine) in Chinese Children

NCT02991872 | Completed Phase 4

• 2 other identifiers: 205634V49_24E1
• Study Type: interventional
• Target: 150
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to evaluate the long-term persistence of immune responses approximately 5 years or more after simulated rabies post-exposure prophylaxis provided in 2012 according to Essen (1-1-1-1-1) or Zagreb (2-1-1) intramuscular (IM) regimens in the subset of subjects who participated in the parent study (V49\_24 \[NCT01680016\]) who were aged ≥6 and ≤17 years at the time of enrollment. This study is aimed to respond to a post-marketing commitment by the China Food and Drug Administration (CFDA) requested at the time of the renewal of the purified chicken-embryo cell rabies vaccine license in China, granted in August 2015.

Conditions

Virus Diseases

Keywords

Persistence; Purified chicken-embryo cell rabies vaccine; Rabies Virus Neutralizing Antibody (RVNA); Immunogenicity; Post-Exposure Prophylaxis (PEP); Rabipur

Outcome Measures

Primary Outcomes (2)

• Rabies Virus Neutralizing Antibody(RVNA) GMCs as measured by rapid fluorescent focus inhibition test(RFFIT) measured in the study, following the Post-Exposure Prophylaxis(PEP) received in the V49_24 (NCT01680016) parent study (Zagreb and Essen regimens).

  Day-1/Visit-1

• Percentage of subjects with RVNA concentration ≥ 0.5 IU/mL measured in this study, following the PEP received in the V49_24 (NCT01680016) parent study (Zagreb and Essen regimens).

  Day-1/Visit-1

Study Arms (1)

V49_24E1 Group

OTHER

Up to 225 subjects, who completed the full PEP rabies regimens in the parent study V49\_24 (NCT01680016), will be invited to participate to this extension study.

Procedure: Blood draw

Interventions

Blood draw PROCEDURE

Subjects aged from ≥6 to ≤17 years at the time of enrolment in the parent clinical trial (following the CFDA post-marketing commitment requirement) and who received the full PEP rabies regimen as an intramuscular injection according to the vaccine group to which they were assigned in the V49\_24 (NCT01680016) study will be invited to take part in this study. Single blood draw from subjects at Day-1/Visit-1. Subjects will be observed for 15 minutes after the blood draw.

V49_24E1 Group

Eligibility Criteria

• Age: 10 Years - 22 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• Subjects with age ≥ 6 and ≤17 at the time of enrollment in the parent study who signed the informed consent prior to the extension study entry, who received the full PEP in the parent study according to either the Zagreb or Essen intramuscular regimens.
• Subjects who or whose parent(s)/legal guardian(s) have voluntarily given written informed consent/assent for this extension study after the nature of the study has been explained according to local regulatory requirements, prior to study entry.
• Individuals who can comply with study procedures.

You may not qualify if:

• Prior to extension study entry, each subject must not have:
• Documented medical history of exposure to rabies or rabies prophylaxis after completion of the parent study (V49\_24 \[NCT01680016\]) and before study start.
• Participated in the parent study (V49\_24 \[NCT01680016\]) but not received the full PEP vaccination course (or received it out of window) following assignment to either Zagreb or Essen regimen during the parent study.
• Progressive, unstable or uncontrolled clinical conditions.
• Clinical conditions representing a contraindication to blood draws.
• Abnormal function of the immune system resulting from:
• Clinical conditions.
• Systemic administration of corticosteroids for more than 14 consecutive days within 90 days prior to informed consent for all age groups.
• Administration of antineoplastic and immunomodulating agents or radiotherapy within 90 days prior to informed consent for all age groups.
• Received immunoglobulins or any blood products within 180 days prior to informed consent for all age groups.
• Study personnel as an immediate family or household member.
• Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the subject due to participation in the study.

Sponsors & Collaborators

• GlaxoSmithKline: lead

Study Sites (1)

GSK Investigational Site

Mengshan, 546700, China

Location

MeSH Terms

Conditions

Virus Diseases

Interventions

Blood Specimen Collection

Condition Hierarchy (Ancestors)

Infections

Intervention Hierarchy (Ancestors)

Specimen Handling; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Punctures; Surgical Procedures, Operative; Investigative Techniques

Study Officials

• GSK Clinical Trials

  GlaxoSmithKline

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: NA
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 9, 2016
• First Posted: December 14, 2016
• Study Start: December 16, 2016
• Primary Completion: March 12, 2017
• Study Completion: March 12, 2017
• Last Updated: April 12, 2017

Record last verified: 2017-04

Locations

CN (1)